Eliyahu Sharon Kalif - Mar 4, 2022 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Signature
/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif
Stock symbol
TEVA
Transactions as of
Mar 4, 2022
Transactions value $
$0
Form type
4
Date filed
3/8/2022, 03:10 PM
Previous filing
Mar 2, 2022
Next filing
Aug 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +21.4K +49.18% 64.9K Mar 5, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award $0 +134K $0.00 134K Mar 4, 2022 Ordinary Shares 134K Direct F1, F2, F3
transaction TEVA Restricted Share Units Options Exercise $0 -21.4K -25% $0.00 64.2K Mar 5, 2022 Ordinary Shares 21.4K Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.
F4 Restricted share units were granted on March 5, 2021, with 21,387 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 21,390 vesting on March 5, 2025.